Literature DB >> 10976984

Corticosteroid osteoporosis: practical implications of recent trials.

P N Sambrook1.   

Abstract

Corticosteroids are widely used and effective agents for control of many inflammatory diseases, but osteoporosis is a common problem associated with their long-term use. Several large double-blind controlled clinical trials in patients with corticosteroid osteoporosis recently have been published, indicating it is possible to prevent or reverse this bone loss. Ultimately, the aim of treatment is to prevent fractures, especially vertebral fractures that are the most common type of fracture associated with corticosteroid therapy, yet it remains unclear exactly which patients should receive prophylaxis. Understanding the differences between these trials is key to interpreting the results, which have important practical implications for patient management.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10976984     DOI: 10.1359/jbmr.2000.15.9.1645

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  11 in total

Review 1.  A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis.

Authors:  S Lekamwasam; J D Adachi; D Agnusdei; J Bilezikian; S Boonen; F Borgström; C Cooper; A Diez Perez; R Eastell; L C Hofbauer; J A Kanis; B L Langdahl; O Lesnyak; R Lorenc; E McCloskey; O D Messina; N Napoli; B Obermayer-Pietsch; S H Ralston; P N Sambrook; S Silverman; M Sosa; J Stepan; G Suppan; D A Wahl; J E Compston
Journal:  Osteoporos Int       Date:  2012-03-21       Impact factor: 4.507

2.  Use of dual energy X-ray absorptiometry in pediatric patients.

Authors:  Halley Wasserman; Jennifer M O'Donnell; Catherine M Gordon
Journal:  Bone       Date:  2016-12-15       Impact factor: 4.398

3.  Practice patterns in patients at risk for glucocorticoid-induced osteoporosis.

Authors:  Adrianne C Feldstein; Patricia J Elmer; Gregory A Nichols; Michael Herson
Journal:  Osteoporos Int       Date:  2005-09-03       Impact factor: 4.507

4.  Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club.

Authors:  Jean-Pierre Devogelaer; Stefan Goemaere; Steven Boonen; Jean-Jacques Body; Jean-Marc Kaufman; Jean-Yves Reginster; Serge Rozenberg; Yves Boutsen
Journal:  Osteoporos Int       Date:  2005-10-11       Impact factor: 4.507

5.  [Prescription of glucocorticoids by rheumatologists in patients with rheumatoid arthritis in Germany].

Authors:  K Thiele; F Buttgereit; D Huscher; A Zink
Journal:  Z Rheumatol       Date:  2005-04       Impact factor: 1.372

6.  Amelioration of the adverse effects of prednisolone by rituximab treatment in adults with steroid-dependent minimal-change nephrotic syndrome.

Authors:  Yoei Miyabe; Takashi Takei; Yuko Iwabuchi; Takahito Moriyama; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2015-07-03       Impact factor: 2.801

7.  Prevention and treatment of glucocorticoid-induced osteoporosis.

Authors:  Jeffrey R Curtis; Kenneth G Saag
Journal:  Curr Osteoporos Rep       Date:  2007-03       Impact factor: 5.096

8.  Low-dose parathyroid hormone and estrogen reverse alkaline phosphatase activity suppressed by dexamethasone in mouse osteoblastic cells.

Authors:  Mei-Fway Iu; Hiroshi Kaji; Junko Naito; Hideaki Sowa; Toshitsugu Sugimoto; Kazuo Chihara
Journal:  J Bone Miner Metab       Date:  2005       Impact factor: 2.626

Review 9.  US and UK guidelines for glucocorticoid-induced osteoporosis: similarities and differences.

Authors:  Juliet Compston
Journal:  Curr Rheumatol Rep       Date:  2004-02       Impact factor: 4.592

Review 10.  Management of osteoporosis in adults with cystic fibrosis.

Authors:  Travis M Hecker; Robert M Aris
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.